



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
November 6, 2018

Therapeutic Class	Drug Name	DURB Recommendations
Antimigraine Agents, Other		
	<i>Aimovig (Subcutaneous) Injection*</i>	NP/PA
Hypophosphatemia Treatments		
	<i>Crysvita (Subcutaneous) Injection*</i>	NP/PA (for coverage on the PADL)
Erythropoiesis Stimulating Proteins		
	<i>Mircera (Intravenous or Subcutaneous) Injection*</i>	NP/PA
Ophthalmics, Glaucoma Agents		
	<i>Rhopressa (Ophthalmic) Solution*</i>	NP/PA
	<i>Vyzulta (Ophthalmic) Solution*</i>	NP/PA
HIV/AIDS		
	<i>Trogarzo (Intravenous) Injection*</i>	P/PA (for coverage on the PADL)
Anticonvulsants		
	<i>Divalproex Sprinkle (Oral) Capsule</i>	P
	<i>Depakote Sprinkle (Oral) Capsule</i>	NP/PA
	<i>Qudexy XR (Oral) Capsule</i>	NP/PA
Antihyperuricemics		
	<i>Mitigare (Oral) Capsule</i>	P
Antipsychotics		
	<i>Latuda (Oral) Tablet</i>	NP/PA
	<i>Aristada Initio (Intramuscular) Injection</i>	P/PA
Colony Stimulating Factors		
	<i>Fulphila (Subcutaneous) Injection</i>	NP/PA
	<i>Neulasta (Subcutaneous) Injection/Kit</i>	NP/PA
COPD Agents		
	<i>Stiolto Respimat (Inhalation) Spray</i>	P
	<i>Combivent Respimat (Inhalation) Solution</i>	P
	<i>Bevespi (Inhalation) Aerosol</i>	NP/PA
Glucocorticoids, Inhaled		
	<i>Aerospan (Inhalation) Aerosol</i>	NP/PA
Ophthalmics, Anti-Inflammatory/Immunomodulator		
	<i>Restasis (Ophthalmic) Multidose Emulsion</i>	NP/PA



For the following therapeutic classes, the DUR Board recommended no changes:

Alzheimer's Agents	Iron, Oral	Ophthalmics for Allergic Conjunctivitis
Antihistamines, First Generation	Methotrexate	Ophthalmics, Anti-Inflammatories
Antineoplastic Agents	Neuropathic Pain	Otics, Anti-Inflammatory
Topical Antipruritics, Topical	NSAIDs	Otic Antibiotics
Bronchodilators, Beta Agonist	Oncology, Oral - Breast	Progestational Agents
Cough and Cold, Cold	Oncology, Oral - Hematologic	Steroids, Topical High
Cough and Cold, Non-Narcotic	Oncology, Oral - Renal Cell	Steroids, Topical Low
Glucocorticoids, Oral	Oncology, Oral - Skin	Steroids, Topical Very High
Intranasal Rhinitis Agents	Ophthalmic Antibiotic-Steroid Combinations	Thrombopoiesis Stimulating Proteins
Immunomodulators, Atopic Dermatitis	Ophthalmic Antibiotics	

*New drug review; DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PADL=Providers' Administered Drug List